PT  - JOURNAL ARTICLE
AU  - E. Kobal
AU  - T. Martynyuk
AU  - O. Arkhipova
AU  - V. Masenko
AU  - S. Nakonechnikov
AU  - I. Chazova
TI  - Bosentan influence on catecholamines levels in patients with idiopathic arterial pulmonary hypertenson
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P953
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P953.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P953.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - Aim: to assess the influence of endothelin receptor antagonist Bosentan on catecholamines levels in pts with idiopathic pulmonary arterial hypertension (IPAH).Methods: In the single-center comparative study we included 35 pts aged 35,2±9,6ys with IPAH confirmed by RHC(WHO Functional Class (FC) II-IV)without systemic inflammation signs.On top of stable therapy with anticoagulants,diuretics,glycosides,calcium antagonists for at least 3 months,Bosentan therapy was started 62,5 mg twice daily for 4 wks.At wk4 the pts were randomized 1:1 by the envelope method to bosentan 125 or 250 mg/day.At baseline, at wk3 and wk12 visits the pts underwent the clinical and lab assessment,including catecholamines(HPLC).Results: At baseline IPAH groups were comparable by age,sex,disease duration,hemodynamic parameters.In both groups the levels of norepinephrine were significantly higher than normal values(139,9±1,2).Otherwise the epinephrine levels were decreased as compared with controls(69,4±1,2).View this table:table1Conclusion: In IPAH pts Bosentan therapy influenced on catecholanines levels by significant reduction of initially increased norepinephrine levels.This effect was more pronounced in Pts treated with Bosentan 125mg daily.